Regulatory issues relating to therapies for periodontal regeneration.
The Food and Drug Administration (FDA) has regulated medical devices since May 1976, when the Medical Device Amendments were enacted. The clinical trial requirements for the marketing of periodontal regeneration devices have been dependent, in part, on the degree of their similarity to devices marketed prior to the legislative enactment date in terms of materials, indication statements, and labeling claims. Nonresorbable barriers were allowed to be marketed based on their equivalence to devices marketed prior to the enactment date based on biocompatability and clinical trial data under the premarket notification requirements section of the law. Bone filling materials such as hydroxyapatite were first marketed based on the finding of equivalence to predicate devices. Newer technologies such as bioabsorbable barriers have also been reviewed under the premarket notification provisions of the law, but manufacturers have been required to provide more extensive safety and effectiveness data to establish equivalence to pre-Amendments devices. Data to answer questions related to the potential toxicity of breakdown products, period of absorption, and ultimate clinical effectiveness needed to be answered prior to marketing. New devices that incorporate technologies that are not substantially equivalent to predicate devices must proceed through the premarket approval route to marketing. For new devices considered a potential significant risk to the patient population, clinical trials are conducted via the investigational device exemption (IDE) requirements that specify the means by which trials will proceed in order to protect the rights of patients. New devices of organic origin, such as bone morphogenic protein, have followed the premarket approval route with IDE requirements instituted as a condition for their path to the marketplace. Issues associated with immediate and long-term contact including potential toxicity, tumorigenicity, and sensitization need to be addressed with appropriate animal models.
Singleton
D G
DG
Food and Drug Administration, Rockville, Maryland, USA.
Torres-Cabassa
A
A
D000818:Animals; D019485:Bone Morphogenetic Proteins / Q000592:standards; D018786:Bone Substitutes / Q000592:standards*; D016025:Bone Transplantation; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence; D003764:Dental Materials / Q000592:standards*; D018795:Device Approval / Q000331:legislation & jurisprudence*; D016557:Guided Tissue Regeneration, Periodontal / Q000295:instrumentation*; D006801:Humans; D008567:Membranes, Artificial; D010510:Periodontal Diseases / Q000601:surgery*; D014481:United States; D014486:United States Food and Drug Administration
D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes; D003764:Dental Materials; D008567:Membranes, Artificial